METHOD OF TREATMENT FOR CHRONIC TRICHOMONIASIS Russian patent published in 2008 - IPC A61K35/74 A61K31/7105 A61P15/00 A61N5/67 A61K31/727 A61K31/4164 A61H7/00 A61K31/44 A61K31/422 A61B5/00 A61K38/43 A61K33/26 A61M1/36 

FIELD: medicine, urology.

SUBSTANCE: susceptibility of pathogenic organism to antiprotozoan drugs is determined. At the preliminary stage sporobacterin, sulodexide, methadoxil, and vobenzyme are injected; the prostate is affected by ultrasound exposure. After that at the etiotropic treatment stage, the blood is taken and separated in plasma, erythrocyte suspension, and leukocyte suspension fractions by sequential centrifuging at 800 rpm and 1800 rpm speed and temperature +4°C. The plasma is eliminated and replaced by crystalloid solution. The erythrocyte suspension is injected intravenously to the patient. The leukocyte suspension, with 0.5 ml ATP added, is affected by semiconductor laser radiation exposure at λ=0.70 mcm, then 0.75 g of metronidazol in solution is added and, after incubation at +37°C, injected to the patient. Simultaneously nifuratel is administered perorally in 200 mg dose twice a day. The procedure is repeated during 8 days. At the rehabilitation therapy stage during 10 days trilact is administered by 2 doses twice a day, as well as polyvitamin mix "Alpha-Vit". The method provides directed metronidazol transport into infection focuses, activates autoblood cells metabolism and phagocytic, adhesive, and migration leukocyte activities, stimulates resorption of fibrotic degenerated chronic inflammation niduses in urino-genital tract, decreases manifestation of side effects.

EFFECT: increase in treatment effectiveness.

2 ex